(Q36309930)

13 August 2017

1 reference

title

Macrolides in cystic fibrosis. (English)

1 reference

13 August 2017

0 references

S C Bell

1

1 reference

13 August 2017

S L Senini

series ordinal

2

1 reference

13 August 2017

J G McCormack

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2005

1 reference

Chronic Respiratory Disease

13 August 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

85-98

1 reference

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

New macrolides: expanded horizons for an old class of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Erythromycin, clarithromycin, and azithromycin: are the differences real?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Clinical relevance of intracellular and extracellular concentrations of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

The anti-inflammatory effects of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Principles of appropriate antibiotic use for treatment of acute bronchitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Principles of appropriate antibiotic use for acute pharyngitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

The use of antibiotics in acne therapy: oral or topical administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Anti-inflammatory effects of macrolides in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Anti-inflammatory effects of macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

The effects of macrolides on inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Macrolide antibiotics and pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Interleukin-8, a chemotactic and inflammatory cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Erythromycin therapy for otitis media with effusion in sinobronchial syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Diffuse panbronchiolitis. A disease of the transitional zone of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Azithromycin, the multidrug-resistant protein, and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Advanced-generation macrolides: tissue-directed antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Comparative safety of the different macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Macrolide antibacterials. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

Inhibition of motility ofPseudomonas aeruginosa andProteus mirabilis by subinhibitory concentrations of azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD066RS

10.1191/1479972305CD066RS

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference